2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 001

WITHDRAWN
Abstract Number: 002

WITHDRAWN
Abstract Number: 003

Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Abstract Number: 004

Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Abstract Number: 005

Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)
Abstract Number: 006

Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Abstract Number: 007

Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
Abstract Number: 008

Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Abstract Number: 009

Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 010

Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
Abstract Number: 011

Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings
Abstract Number: 012

Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Abstract Number: 013

A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Abstract Number: 014

Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Abstract Number: 015

Normal MRI Appearance of Marrow Adjacent to the Sacroiliac Joints in Healthy Children During Development

1
2
3
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].